New molecular strategies for early lung cancer detection

Cancer Investigation

Volumn 18, Issue 6, 2000, Pages 555-563

  Montuenga, Luis M ^a   Mulshine, James L ^b,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MSC 1906 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; BIOLOGICAL MARKER; BUDESONIDE; CYCLOOXYGENASE 2; CYTOKINE; DNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GASTRIN RELEASING PEPTIDE; GROWTH FACTOR; MONOCLONAL ANTIBODY; MYC PROTEIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN P16; PROTEIN P53; PROTEINASE; RETINOID; RIBONUCLEOPROTEIN; RNA; SERUM ALBUMIN; SILICON DIOXIDE; SOMATOMEDIN C;

APOPTOSIS; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; GENE EXPRESSION; HETEROZYGOSITY LOSS; HUMAN; IMMUNOCYTOCHEMISTRY; LUNG CANCER; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SMOKING; SPUTUM CYTODIAGNOSIS; THORAX RADIOGRAPHY; TUMOR SUPPRESSOR GENE;

EID: 0033926719     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009012195     Document Type: Review

References (65)

1. Mulshine JL: Lung cancer: current progress, future promise. Primary Care Cancer 18:9-12, 1998.
2. Peto R, Lopez AD, Boreham J, et al. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 339:1268-1278, 1992.
3. Gaffney M, Altshuler B: Examination of the role of cigarette smoke in lung carcinogenesis J Natl Cancer Inst 80:925-931, 1988.
4. Ruckdeschel JC: Chemotherapy for lung cancer: new agents with significant benefit. Primary Care Cancer 18:26-32, 1998.
5. Satoh H, Ishikawa H, Yamashita YT, et al: Outcome of patients with lung cancer detected by mass screening versus presentation with symptoms. Anticancer Res 17:2293-2296, 1997.
6. Auerbach O, Stout AP, Hammond C, et al: Changes in the bronchial epithelium in relation to cigarrette smoking and in relation to lung cancer. N Engl J Med 265:253-267, 1961.
7. Slaughter DP, Southwick HW, Smejkal W: "Field cancerization" in oral stratified squamous epithelium. Cancer 6:963-968, 1953.
8. Papanicolaou GN: Diagnostic value of exfoliated cells from cancerous tissue. JAMA 131:372, 1946.
9. Papanicolaou GN, Traut HF: The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 42:193, 1941.
10. Saccomanno G, Archer VE, Auerbach O: Development of carcinoma of the lung or reflected in exfoliated cells. Cancer 33:256-270, 1974.
11. Brett GZ: Earlier diagnosis and survival in lung cancer. Br Med J 4:260-262, 1969.
12. Boucot KR, Weiss W: Is curable lung cancer detected by semiannual screening? JAMA 224:1361-1365, 1973.
13. Bailar JC: Early lung cancer cooperative study group: early lung cancer detection. Summary and conclusion. Am Rev Respir Dis 130:565, 1984.
14. rost JK, Ball WC, Levin ML, et al: Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins Study. Am Rev Respir Dis 130:549-554, 1984.
15. Mulshine JI, Tockman MS, Smart CR: Consideration in the development of lung cancer screening tools. J Natl Cancer Inst 81:900-906, 1989.
16. Yershov G, Barsky V, Belgovskiy A, et al: DNA analysis and diagnostics on oligonucleotide microchips. Proc Natl Acad Sci USA 93:4913-4918, 1996.
17. Eggers M, Hogan M, Reich RK, et al: A microchip for quantitative detection of molecules utilizing luminescent and radioisotope reporter groups. Bio Techniques 17:516-525, 1994.
18. Emmert-Buck MR, Bonner RF, Smith PD, et al: Laser capture microdissection. Science 274:998-1001, 1996.
19. Brambilla E: Early lung cancer detection. In: Clinical and Biological Basis of Lung Cancer Prevention, edited by Y Martinet, JM Vignaud, N Martinet, and JL Mulshine. Basel, Switzerland, Birkhauser, 1998.
20. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990.
21. Mulshine JL, Scott F: Molecular markers in early cancer detection. New screening tools. Chest 107:280s-286s, 1995.
22. Gazdar AF, Carbone DP, eds: The Biology and Molecular Genetics of Lung Cancer, Austin: RG Landers Co., 1994.
23. Rodenhuis S, van de Wetering ML, Mooi WJ, et al: Mutational activation of the K-ras oncogene in lung adenocarcinoma: a possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317:929-935, 1987.
24. Westra WH, Slebos RJC, Offerhaus GJA et al: K-ras oncogene activation in lung adenocarcinomas from former smokers. Cancer 72:432-438, 1993.
25. Sugio K, Fukuyama Y, Sakada T, et al: Second primary cancers after resection of lung adenocarcinoma with ras gene mutation. Anticancer Res 18:3395-3398, 1998.
26. Hensel CH, Hsieh CL, Gazdar AD, et al: Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer Cancer Res 50:3067-3072, 1990.
27. Reissmann PT, Koga H, Takahashi R, et al: Inactivation of the retinoblastoma gene in non-small-cell lung cancer Oncogene 8: 1913-1919, 1993.
28. Betticher DC, Heighway J, Hasleton PS, et al: Prognostic csignificance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer Br J Cancer 73:294-300, 1996.
29. Guzdar A: The molecular pathogenesis of lung cancer and other epithelial tumors. In: Premalignancy and Tumor Dormancy, edited by E Yefenof, RH Sheuermann, R.G. Iandes Co., 1996.
30. Sundaresan V, Ganly P, Hasleton P, et al: p53 and chromosome 3 abnormalities, characteristic of malignant lung tumors, are detectable in preinvasive lesions of the bronchus. Oncogene 7: 1989-1997, 1992.
31. Chung GTY, Sundaresan V, Haselton P, et al: Sequential molecular genetic changes in lung cancer development. Oncogene 11: 2591-2598, 1995.
32. Scott FM, Moduli R, Lehman TA, et al: High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer. Clin Cancer Res 3:479-482, 1997.
33. Mao L, Lee JS, Kurie JM, et al: Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89:857-862, 1997.
34. INK4A inactivation in non small-cell lung cancers. Oncogene 16:497-505, 1998.
35. INK4/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res, 55:1448-1451, 1995.
36. Cairns P, Polascik TJ, Eby Y, et al: Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat Genet 11: 210-212, 1995.
37. INK4a in primary rat lung tumors. Mol Cell Biol 17:1366-1374, 1997.
38. Belinsky SA, Nikula KJ, Palmisano WA, et al: Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95: 11891-11896, 1998.
39. Westra WH, Baas IO, Hruban RH, et al: K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 56:2224-2228, 1996.
40. Jensen-Taubman SM, Steinberg SM, Linnoila RI: Bronchiolization of the alveoli in lung cancer: pathology patterns of differentiation and oncogene expression. Int J Cancer 75:489-496, 1998.
41. INK4 - Cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 5:243-250, 1999.
42. Sozzi G, Pastorino U, Moiraghi L, et al: Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 58: 5032-5037, 1998.
43. Brambilla E, Gazzeri S, Lantuejoul S, et al: P53 mutant immunophenotype and deregulation of P53 transcription pathway (Bc12, Bax, Wafl) in precursor bronchial lesions of lung cancer. Clin Cancer Res 4:1609-1618, 1998.
44. Wolff H, Saukkonen K, Anttila S, et al: Expression of cyclooxigenase-2 in human lung carcinoma. Cancer Res 58:4997-5001, 1998.
45. Herschmann HR: Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 60:281-319, 1991.
46. Martinez, A. Treston AM, Saldise L, et al: Expression of peptidylglycine alpha amidating mono-oxygenase in morphological abnormalities adjacent to pulmonary tumors. Am J Pathol 149:707-716, 1996.
47. Tockman MS, Gupta PK, Myers JD, et al: Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: A new approach to early lung cancer detection. J Clin Oncol 6:1685-1693, 1988.
48. Tockman MS, Mulshine JL, Piantadosi S, et al: Prospective detection of preclinical lung cancer: results from two studies of hnRNP expression. Clin Cancer Res 3:2237-2246, 1997.
49. Zhou J, Mulshine JL, Unsworth EJ, et al: Purification and characterization of a protein which permits early detection of lung cancer: identification of heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) as the antigen for monoclonal antibody 703D4. J Biol Chem 271:10760-10766, 1996.
50. Zhou J, Mulshine JL, Ro JY, et al: Expression of heterogeneous nuclear ribonucleoprotein A2/B1 in bronchial epithelium of chronic smokers. Clin Cancer Res 4:1631-1640, 1998.
51. Zhou J, Jensen SM, Steinberg SM, et al: Expression of early lung cancer detection marker p31 in neoplastic and non-neoplastic respiratory epithelium. Lung Cancer 14:85-97, 1996.
52. Man YG, Martinez A, Avis IM, et al: Phenotypically different cells with hnRNP A2/B1 expression show similar genetic alterations. Proc Am Assoc Cancer Res, 2000 (in press).
53. Montuenga LM, Zhou J, Avis I, et al: Dynamic changes of expression of heterogeneous nuclear ribonucleoprotein A2/B1 correlate with developmental stages of mammalian lung. Am J Mol Cell Respir Biol 19:1-9, 1998.
54. Nakanishi Y, Mulshine JL, Kasprzyk P, et al: Small cell lung cancer cells autostimulate their growth via an insulin-like growth factor-I activity: evaluation of 4 cell lines. J Clin Invest 82:354, 1988.
55. Cuttitta F, Carney DN, Mulshine JL, et al: Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316:823-826, 1985.
56. Suarez Pestana E, Greiser U, Sanchez B, et al: Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s). Br J Cancer 75:213-220, 1997.
57. Rachwal WJ, Bongiorno PF, Orringer MB, et al: Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br J Cancer 72:56-64, 1995.
58. Cuttitta F, Montuenga LM, Garayoa M, et al: The role of adrenomedullin as a growth regulatory peptide in the normal and malignant setting. J Anim Sci 77(Suppl 3):55-69, 1999.
59. Miller MJ, Martinez A, Montuenga LM, et al: Adrenomedullin: a pluripotent peptide with growth regulatory function. In: Adrenomedullin, edited by A Martinez, F Cuttitta, IOS Press/Ohmsha Ltd., Amsterdam and Tokyo, 1998, pp. 171-183.
60. Meyskens FL, Goodman GE, Alberts DS: 13-cis-Retinoic acid: pharmacology, toxicology and clinical application for the prevention and treatment of human cancer. Crit Rev Oncol Hematol 3: 75-101, 1985.
61. Avis I, Mathias A, Unsworth EJ, et al: Analysis of small cell lung cancer growth inhibition by 13-cis-retinoic acid: importance of bioavailability. Cell Growth Diff 6:485-492, 1995.
62. Mulshine JL, DeLuca LM, Dedrick RL: Regional delivery of retinoids: a new approach to early lung cancer intervention. In: Clinical and Biological Basis of Lung Cancer Prevention, edited by Y Martinet, JM Vignaud, N Martinet, and JL Mulshine, Basel, Switzerland, Birkhauser, 1998, pp 273-283.
63. Patton JS: Mechanisms of macromolecule absorption by the lung. J Adv Drug Delive Rev 19:3-36, 1996.
64. Wattenberg LW, Wiedmann TS, Estensen RD, et al: Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 57:5489-5492, 1997.
65. Chang M, Chien-Jen C, Lai M, et al: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 336:1855-1859, 1997.